Equine sarcoïds – Part 2: current treatment modalities

Equine sarcoïden – Deel 2: huidige behandelingsmogelijkheden

L. Bogaert, A. Martens, P. Depoorter, F. Gasthuys

Department of Surgery and Anesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Salisburylaan 133, B-9820 Merelbeke, Belgium

lies.bogaert@UGent.be

ABSTRACT

Treatment of sarcoïden is often challenging, due to the variable clinical presentation of lesions and the frequent local recurrences. In this article, both the surgical and the non-surgical treatment of equine sarcoïden are reviewed. It is generally accepted that the prognosis is worse if unsuccessful attempts have been made previously. Therefore, the best available treatment option should always be used at the first attempt of treatment. Different surgical approaches have been reported, including conventional excision, cryosurgery and CO₂ laser surgery. Success rates are high if a non-touch approach, wide surgical margins and general anesthesia can be applied. Local chemotherapy is a valuable addition in the treatment of sarcoïden and can be combined with surgery. Radiotherapy is a very successful treatment, but safety precautions prevent routine application. Local immunotherapy including Bacillus Calmette-Guérin vaccination and imiquimod cream are commonly applied treatments which induce rather effective tumour regression.

SAMENVATTING

De behandeling van sarcoïden is vaak een uitdaging door het variabel klinisch gedrag en het frequent optreden van lokale recidieven. In dit artikel wordt een overzicht gegeven van zowel de chirurgische als niet-chirurgische behandeling van equine sarcoïden. Algemeen wordt aangenomen dat de prognose slechter wordt indien een eerderere behandeling vruchteloos bleek. Daarom is het van belang om bij de behandeling onmiddellijk de best mogelijke optie aan te wenden. Verschillende chirurgische benaderingen worden beschreven, waaronder de conventionele excisie, cryochirurgie en CO₂-laserbehandeling. Het slagingspercentage is hoog indien een “non-touch” benadering, de wegneming van brede randen normale huid en een algemene anesthesie worden toegepast. Lokale chemotherapie is een waardevolle aanvulling bij de behandeling van sarcoïden en kan gecombineerd worden met chirurgie. Bestraling is een andere succesvolle behandeling, maar strenge veiligheidsmaatregelen belemmeren een routinematige toepassing ervan. Lokale immunotherapiën, zoals de vaccinatie met Bacillus Calmette-Guérin en imiquimod crème, worden regelmatig toegepast en resulteren in behoorlijk goede tumorregressie.

INTRODUCTION

The treatment of equine sarcoïden has always been challenging, due to the variable clinical presentation of lesions and the frequent local recurrences. Therefore, careful selection of the appropriate treatment for each sarcoïd and each horse should be made, taking into account the localization, number and size of the tumors, the treatment history, the financial value of the animal and the owner compliance to fulfil the treatment schedule (Marti et al., 1993; Carstanjen and Lepage, 1998).

Both surgical and non-surgical techniques have been described with variable success rates. Since none of the current techniques has been proven to be 100 % successful (Marti et al., 1993), the confidence of owners in conventional treatments may decrease, leading them to use a whole scale of topical ointments (including toothpaste), homeopathy,... Despite the lack of any scientific evidence, tumor regression can occasionally be seen after these alternative therapies. Cure, however, may also be a result of spontaneous regression, which is observed in up to 32 % of the cases (Brostrom, 1995; Martens et al., 2001b). Therefore, benign neglect can be an option, especially in case of small tumors (Knottenbelt et al., 1995; Pascoe and Knottenbelt, 1999). Careful monitoring is yet very important, since aggravation can happen anytime without an obvious reason. It should be kept in mind that not all horses with equine sarcoïden can be cured: in horses with a very large number of sarcoïden, or with sarcoïden with a very large surface, treatment may be impossible. Even in case of a small single sarcoïd owners should be warned about possible local recurrence and deterioration of the sarcoïd (Knottenbelt et al., 1995; Carstanjen and Lepage, 1998). Moreover, the development of new sarcoïden on other locations is always possible (Brostrom, 1995; Carstanjen et al., 1997; Carstanjen and Lepage, 1998). It is generally accepted that the prognosis...
for treatment is significantly worse if one or more unsuccessful attempts have been made previously (Knottenbelt and Walker, 1994). Therefore, the best available treatment option with the highest chance of success should always be used at the first attempt of treatment (Pascoe and Knottenbelt, 1999).

In this paper, only the most commonly applied treatments in equine practice will be presented. Treatments with only anecdotic evidence, such as Sanguinara canadensis (XXTerra®), photodynamic therapy, homeopathy, acupuncture, ligation, hyperthermia and various topical ointments will not be discussed further (Hoffman et al., 1983; Schwierczena, 1993; Brostrom, 1995; Thoresen, 1995; Pascoe and Knottenbelt, 1999; Martens et al., 2000; von Felbert et al., 2005).

**SURGICAL TREATMENT**

**Conventional excision**

Surgical excision of equine sarcoids has been applied for decades with variable success. High recurrence rates of 40 to 72 % are reported (Ragland, 1970; Diehl et al., 1987; Mcconaghy et al., 1994; Brostrom, 1995). This can be attributed to the infiltrative nature of the tumor and auto-transplantation of tumor cells during the surgical procedure (Klein, 1990; Howart, 1990). On histology, fronds of tumor cells infiltrating the surrounding dermis and sometimes the underlying tissues can be observed (Ragland, 1970; Tarwid et al., 1985). The detection of BPV DNA at the surgical margin of an excised sarcoid correlates with an increased risk of recurrence (Martens et al., 2001a). When the excision is performed with wide normal skin margins (at least 12 mm; Figure 1) and a non-touch approach (i.e. changing of gloves and material after tumor removal and extensive flushing of the wound), auto-inoculation with tumor cells and viral material can be avoided and success rates of more than 80 % are achieved (Howart, 1990; Brostrom, 1995; Martens et al., 2001b). Another major factor in the prognosis is the possibility to perform the excision under general anesthesia (80 % success) compared to working on the standing horse (24 % success). General anesthesia provides the surgeon a clear view on the sarcoids, a good ability to remove wide margins and creates good conditions to avoid auto-inoculation (Brostrom, 1995).

**CO₂ laser surgery**

Excision with the CO₂ laser is an efficient tool for the treatment of equine sarcoids. Success rates range from 60 to 89 % (Diehl et al., 1987; Vingerhoets et al., 1988; Carstanjen et al., 1997; Martens et al., 2001b). Large masses are commonly laser-excised using the same approach as described for the conventional excision. Small or flat lesions can be entirely vaporized with the CO₂ laser (Diehl et al., 1987; Vingerhoets et al., 1988; Carstanjen et al., 1997; Weigand et al., 1997). Laser ablation causes less damage to the surrounding tissues and less spread of malignant cells to healthy regions compared to sharp surgical excision with mechanical tools (Carr, 2006). However, poor cosmetic results including scar tissue formation, alopecia, leucotrichia and transient abnormal hair color can sometimes be observed (Vingerhoets et al., 1988; Carstanjen et al., 1997). Other drawbacks are the cost of the equipment and the required safety precautions against burns, fire, eye damage and smoke inhalation (Palmer, 1989).

**Cryosurgery**

Both in human and veterinary medicine cryosurgery has become an accepted way of treating malignancies. Cell death is obtained by repeated freeze-thaw cycles, with optimal cryonecrosis achieved by rapid freezing and slow thawing of the tissue (Farris et al., 1976; Fretz and Barber, 1980). Prior to freezing, large sarcoid masses are debulked to the level of the surrounding skin or even lower, followed by freezing of the tumor base and a normal skin margin with liquid nitrogen (Figure 2). Tissue should be frozen to at least -20 to -25 °C. Temperature control is essential and can be obtained with thermocouple needles (Farris et al., 1976). After the procedure, a black lea-

---

**Figure 1.** Demarcation of a normal skin margin of 12 mm to perform excision of a fibroblastic sarcoid.

**Figure 2.** Continuous circulation contact probes for cryosurgery of debulked sarcoid lesions. Tissue temperature is monitored carefully with thermocouple needles inserted into the tumor mass.
Intralesional chemotherapy is based on achieving a high drug concentration over time in the tumor while sparing normal tissue. The general circulation is bypassed and a low systemic exposure is obtained, thereby minimizing toxicity (Theon, 1998). Due to its cutaneous localization, sarcoids are most convenient for local chemotherapy.

Intralesional injection of cytotoxic drugs directly into the tumor allows higher intratumoral drug concentrations and permits accurate placement of the drug within the tumor (Theon, 1998; Mair and Couto, 2006). The beneficial effects are enhanced if drug carriers that prolong the persistence of the drug in the tumor are used. Viscous fluid preparations such as sesame seed or almond oil are frequently used to achieve this effect (Theon et al., 1993). The most widely used drug in this manner is cisplatin with a 2-year local control rate of approximately 90 % (Theon et al., 1993; Theon et al., 1994; Theon, 1998). Intraläsional cisplatin can be effective as the sole treatment for small sarcoids, but for large tumors the combined use with surgery is recommended (Theon et al., 1994; Theon, 1998). Local cisplatin injected at the time of surgical sarcoid excision was shown not to have any adverse effect on wound healing (Theon et al., 1994). Emulsions are made up from 1 ml of an aqueous solution of 10 mg cisplatin and 2 ml sesame oil and are mixed using 2 syringes and a 3-way valve (Figure 3). A dose rate of 1 mg cisplatin/cm² of tumor can be applied. The sarcoid as well as a margin of normal skin of 1-2 cm should be injected using a parallel-row or field-block technique (Theon et al., 1997). A standard treatment protocol includes 4 injections at 2-week intervals. Side effects of treatment are strictly local (inflammation, swelling, focal ulceration) and self-limiting (Theon, 1998). Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended after each treatment session to prevent acute clostridial infection. The cosmetic and functional results are excellent (Theon, 1998). Alternative cisplatin formulations with almond oil or epinephrine as well as local chemotherapy with bleomycin and 5-fluorouracil (5-FU) are described but appear to be less effective (Bouré et al., 1991; Doyle, 1998; Knottenbelt and Kelly, 2000; Stewart et al., 2006).

Topical chemotherapy has been used for over 100 years to treat equine sarcoids. However, the effect of only a few of these drugs has been studied scientifically. 5-FU can be applied as a cream for single, small occult or verrucous sarcoids but also for larger areas of occult or verrucous sarcoids that are not amendable to any other form of treatment. Due to poor diffusion and inadequate distribution from the surface to the deep margins, the use of 5-FU should be limited to flat lesions (Theon, 1998). Topical 5-FU needs to be applied daily for 30-90 days. Alternatively, it can be applied less frequently under a bandage (Roberts, 1970). A success rate of 66 % was observed (Knottenbelt and Kelly, 2000). To aid the penetration through the epidermis, 5-FU can be mixed with podophylin, an irritant cathartic (Mcconaghy et al., 1994; Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Unlicensed topical ointments (AW-3-LUDES and AW-4-LUDES) containing a variety of heavy metals with minimal inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal. Prophylactic antibiotic therapy and anti-inflammatory drugs are recommended (Pascoe and Knottenbelt, 1999). The treated area can show a marked inflammatory reaction, but scarring is usually minimal.
(Knottenbelt and Walker, 1994). The success rate decreases by 30 to 40% for each previous unsuccessful treatment.

Radiotherapy

Radiotherapy induces tumor destruction by ionizing radiation. The most frequently used radiotherapy method in horses is interstitial brachytherapy with iridium-192 reporting one- and five-year progression-free survival rates of 87 and 74% respectively for non-ocular sarcoids and 98-100% for periorcular sarcoids (Wyn-Jones, 1983; Turrel et al., 1985; Theon and Pascoe, 1995; Knottenbelt and Kelly, 2000; Byam-Cook et al., 2006). It involves the implantation of sealed radioactive sources within the tissue to treat the tumor at short source-object distances. Because of the long half-life of iridium-192 (74.2 days), the implants are removed once the required dose has been administered, usually after 5 to 6 days. The primary advantage is that high radiation doses can be given directly into the tumor with minimal damage to the surrounding tissues (Henson and Dobson, 2004). The technique is very suitable for tumors on locations where surgical excision is not possible (eyelids, commisures of lips) and good results have been obtained for recurrent sarcoids. Local complications such as necrosis and infection and minor cosmetic defaults (leucotrichia, alopecia, minimal scarring) have been observed (Turrel et al., 1985; Theon and Pascoe, 1995; Theon, 1998; Byam-Cook et al., 2006). A major drawback of this otherwise valuable treatment is the safety of the operators and the need for patient isolation (Wyn-Jones, 1979; Walker et al., 1991).

Immunotherapy

The purpose of immunotherapy is to enhance the ability of the host to reject the tumor. Antitumoural effects are produced primarily through enhanced immunologic activity. Many immunostimulants have been evaluated in horses, including Bacillus Calmette-Guérin (BCG) vaccine, autovaccination and imiquimod 5% cream.

BCG is an attenuated strain of Mycobacterium bovis originally developed as a tuberculosis vaccine in man and is currently still in use for intravesical treatment of superficial bladder cancer (Brake et al., 2000). Live organisms, dead organisms and cell wall extracts have been used in combination with various adjuvants for intratumoral injection of equine sarcoids. Tumor regression involves both non-specific and specific mechanisms and is based on a delayed hypersensitivity reaction (Morton and Barth, 1995). BCG vaccination consists of multiple injections into the tumor mass and tumor bed to ensure complete infiltration of the target volume. Most commonly 4 injections at a 2-3 week interval are performed. The success rate ranges from 60-100% and is mainly dependent on tumor size and localization (Klein et al., 1986). Periorcular sarcoids are most responsive to treatment with local control rates up to 100%. Sarcoids on the limbs respond poorly and vaccination can result in massive oedema formation, lymphangitis or even septic arthritis (Klein et al., 1986; Owen and Jagger, 1987; Theon, 1998). Cytoreductive surgery prior to treatment of bulky tumors is recommended (Theon, 1998). General (anaphylactic shock, death, fever) and local (oedema, purulent discharge, ulceration) side effects have been described and therefore administration of non-steroidal or steroidal anti-inflammatory drugs is recommended prior to BCG vaccination (Theon, 1998).

Autogenous vaccination of sarcoids has been performed with variable success rates. Although promising results of autovaccination combined with food supplements have been reported (Kimmunen et al., 1999), other authors have reported worsening of the condition or new sarcoïd development after autovaccination (Knottenbelt et al., 1995; Pascoe and Knottenbelt, 1999).

Imiquimod (Aldara™) is an immune response modifier with potent antiviral and antitumoral activity showing promising results for the treatment of equine sarcoïds. Successful treatment of human anogenital warts, actinic keratosis and superficial basal cell carcinoma has been reported (Beutner et al., 1998; Marks et al., 2001; Salasche et al., 2002). Recent studies have shown good results for the treatment of equine sarcoïds (Nogueira et al., 2006; own unpublished results). Treatment consists of application of a thin layer of cream on the tumor surface 3 times a week during several weeks to months. In one study, 60% of the treated sarcoïds resolved entirely and another 20% showed more than 75% reduction, most of them being recurrences after previous treatment (Nogueira et al., 2006). Local side effects, such as ulceration, pain and depigmentation are often observed.

LITERATURE


Thon A.P., Pascoe J.R., Madigan J.E., Carlson G., Metzger L. (1997). Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of


**OPROEP**

**Onderzoek naar equine sarcoïd**

Op de Vakgroep Heelkunde en Anesthesie van de Huisdieren van de Faculteit Diergeneeskunde te Merelbeke loopt momenteel een onderzoek naar de transmissie van het boviniene papillomavirus. Hiervoor zijn we op zoek naar proefpaarden met equine sarcoïden, evenals naar paarden die vroeger reeds behandeld werden voor sarcoïden maar nu sarcoïd-vrij zijn. Deze paarden zullen gebruikt worden om de exacte manier van transmissie te ontrafelen, uitgaande van viraal materiaal afkomstig van zowel runderen als van paarden. Opegelet: deze paarden zullen worden overgekocht door de vakgroep en kunnen dus niet in het bezit blijven van de eigenaar! Indien u in uw cliënteel dergelijke dieren hebt die anders toch moeten geëuthanaseerd of geslacht worden, kunt u ons steeds contacteren voor overname van deze dieren.

Contact: Pieter Depoorter (pieter.depoorter@UGent.be), Lies Bogaert (lies.bogaert@UGent.be)

---

**Vita-Vitaal**

extra gezond resultaat!

Vita-Vitaal is een jonge, snelgroeiende organisatie, gericht op de grote veehouderijbedrijven. Wij beheren een aantal specifieke voedingsproducten met internationale impact. Voor onze solide, technische productondersteuning zijn wij op zoek naar een enthousiaste en ondernemende Dierenarts werkgebied Brabant-Limburg

Binnen ons team past een praktisch ingestelde (ervaren) persoonlijkheid met uitstekende communicatieve vaardigheden. Uw kennis is voornamelijk gericht op diergezondheidsaspecten in de varkenshouderij. Voedingskundige know how kunnen wij uiterst nauwgezet aanvullen, waardoor uw specialiteiten diergezondheid, voeding en zoötechniek optimaal tot hun recht komen. Vita-Vitaal biedt de juiste kandidaat een uiterst boeiende en zelfstandige functie. U onderhoudt waardevolle contacten met veehouders in de intensieve veehouderij, studieclubs en collega’s. Tevens neemt u zitting in ons managementteam. Onze primaire en secundaire arbeidsvoorwaarden zijn solide en bijzonder goed te noemen.

Belangstellenden kunnen hun schriftelijke sollicitatie binnen 21 dagen richten aan: Vita-Vitaal, t.a.v. de heer drs. R. Fourier, postbus 21, 6114 ZG Susteren. U kunt ook per e-mail reageren: info@vita-vitaal.nl. Telefonische informatie betreffende deze vacature kunt u verkrijgen bij de heer drs. R. Fourier, (Managing Director and Technical Support), tel: +32 495201478.